US pharma executives reveal their attitudes to the UK and Brexit
What will Brexit mean for pharma companies on both sides of the Atlantic? Given the ‘special relationship’ between the US and UK – and the particular track record of collaboration in the pharma industry – many people within and beyond the industry are trying to assess what the future will now hold. In order to try to determine this, life sciences expert Alacrita conducted a survey to gauge the views of C-suite biotech executives in the US. The results, outlined…
You might be interested in
